Search Results

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. Be sure to subscribe to our podcast to receive notifications when new episodes are released! 2025 2024 2023 2022 2021 2025 2025 LISTEN 2024 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2024 2023 2023 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2022 2022 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2021 2021 LISTEN LISTEN LISTEN LISTEN LISTEN

<< Go back to the Podcast page EPISODE 40: NEN TREATMENTS: FOCUS ON EXTERNAL RADIATION THERAPY Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. MEET DR. WILLIAM C. CHEN Dr. William C. Chen is a radiation oncologist and translational researcher. Dr. Chen received his undergraduate degree from Johns Hopkins University and completed medical school at the University of California, San Francisco. He completed his internal medicine preliminary internship at Kaiser San Francisco, followed by a residency in Radiation Oncology at UCSF. He is a Chan Zuckerburg Biohub Physician Scientist Fellow and a Helen Diller Family Cancer Center Physician Scientist Program in Clinical Oncology (PSPCO) Fellow. His research focuses on biomarker development, informatics, and clinical trial development with a focus on meningiomas and other malignancies of the central nervous system and beyond. MEET DR. ALEXANDRA HOTCA-CHO Dr. Hotca specializes in treating gastrointestinal cancers, with expertise in advanced radiation therapy techniques such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic body radiation therapy (SBRT), and respiratory gating. These approaches are designed to optimize treatment outcomes and minimize side effects. Her research focuses on enhancing patient quality of life through preventive strategies and identifying predictive biomarkers for radiation-induced toxicities. Dr. Hotca is dedicated to providing exceptional care to the diverse patient community at UCSF. TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY: 1. What is radiation oncology? How does it work? How is it different from other types of radiation? 2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective? Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used? Is there a number or size limit of the tumor(s)? 4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it? If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT? If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated? How common is increased pain after treatment to the bone? What causes that? 5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?) Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans? How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they? Is there a risk with fertility? What other risks are there? 6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give? 9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor? How do you know if the treatment “worked”? Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment? RESOURCES READ Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 41: TOP 10 HIGHLIGHTS OF THE 2024 NANETS SYMPOSIUM Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community. MEET DR. GUILLAUME PEGNA Dr. Pegna is a medical oncologist specializing in caring for adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas, as well as other gastrointestinal cancers. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient and supporting them through their treatment journeys. TOP 10 ABSTRACTS AT THE 2024 NANETS SYMPOSIUM: View the abstracts in the NANETS 2024 Symposium Abstract Guide Improving our understanding of PRRT/optimizing therapy: Mosalem et al. Abstract C-19 Safety of Lutetium-177 DOTATATE Treatment in Patients with Advanced Neuroendocrine Tumors and Extensive/ Innumerable Bone Metastases Singh and Iyer et al. Abstract O-13 Prevalence of CHIP Mutations in patients with Neuroendocrine Tumors and Role in Predicting Hematologic Toxicity to PRRT and Chemotherapy Fidelman et al. Abstract C-27 A Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases Alpha PRRT is Coming Wahl et al. Abstract C-37 Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs) Strosberg et al. Abstract C-16 Targeted Alpha Therapy with 212Pb-DOTAMTATE in subjects with advanced somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors Halperin et al. Abstract C-17 ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors progressing after 177Lu somatostatin analogue therapy: Phase 1b safety/efficacy Novel Treatments/Treatment Combinations Chauhan et al. Abstract C-5 Once-daily Oral Paltusotine in the Treatment of Patients With Carcinoid Syndrome: Results From a Phase 2, Randomized, Parallel-Group Study D’Souza, Soulen et al. Abstract C-29 Initial Outcomes of Integrating Yttrium-90 Radioembolization with Capecitabine-Temozolomide for Grade 3 Liver-Dominant Metastatic Neuroendocrine Tumors Improving Our Understanding of NETs: Basic, Translational, and Epidemiologic Studies of NETs Liu and Yao: Abstract B-1 Development of innovative in vitro and in vivo patient[1]derived cancer models for translational studies in G1/G2 gastroenteropancreatic neuroendocrine tumors Estrada and Bergsland et al. Abstract O-2 Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O'Toole, D., Ge, P. S., Jain, D., Dasari, A., Anaya, D. A., Bergsland, E., Mittra, E., Wei, A. C., Hope, T. A., Kendi, A. T., Thomas, S. M., Flem, S., Brierley, J., Asare, E. A., Washington, K., … Shi, C. (2024). Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors . CA: a cancer journal for clinicians , 74 (4), 359–367. https://doi.org/10.3322/caac.21840 ABOUT NANETS The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the November 21-23, 2024 NANETS Symposium, there are many more noteworthy abstracts found (or listed) here: NANETS Abstract Library 2024 NANETS Abstracts Booklet While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers. RESOURCES WATCH Dr. Will Pegna Discusses Highlights from the 2024 NANETS Symposium LISTEN Top 10 Highlights of the 2023 NANETS Symposium Top 10 Highlights of the 2022 NANETS Symposium DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Other Belzutifan/MK-6482 in PNET + PPGL + VHL ENET STUDY: Quality of Life and Well-Being for NET Patients

Clinical Trials Guide LATEST ON CLINICAL TRIALS Research / Clinical Trials Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 05:10 Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC • Dr. Aman Chauhan Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC. Recorded: June 20, 2024 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 05:44 Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC • Dr. Aman Chauhan Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC. Recorded: June 20, 2024 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 08:26 DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) • Dr. Aman Chauhan Boehringer Ingelheim is sponsoring a phase 1 study, a phase 1 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific or “BiTE”) that may help the immune system fight cancer. The study is in adults with extensive stage small cell lung cancer who have previously received platinum-based chemotherapy and are eligible to receive topotecan treatment. The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with topotecan, a chemotherapy treatment called topoisomerase 1 inhibitor, that works by blocking a chemical (topoisomerase 1) that helps cancer cells repair and separate DNA when they divide. Participants get BI 764532 and topotecan as infusions into a vein. As an alternative, topotecan may also be taken orally (tablets). Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 11:35 LACNETS • Lu177 Dotatate PRRT + M3814 (Peposertib) • Dr. Aman Chauhan Dr. Aman Chauhan discusses Lutetium Lu 177 dotatate in combination with M3814 (peposertib). IDENTIFIER (ClinicalTrials.gov): NCT04750954 Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 04:48 June 2024: Dr. Aman Chauhan Discusses the Alpha PRRT with Pb-212 VMT Study Dr. Aman Chauhan Discusses the Alpha PRRT with Pb-212 VMT Study. Recorded June 2024. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 08:42 June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study. Recorded in June 2024. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Play Video Play Video 13:45 April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine Study Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study. Recorded in April 2023. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Browse by Trial: ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Belzutifan-MK-6482 in PNET + PPGL + VHL CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors CDK4/6 Abemaciclib GEP-NETS CHM-2101 CAR-T cell for GI Cancers ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib in NETs Lu-177 DOTATATE vs Everolimus in Lung NETs Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs Lu-177 DOTATATE + Olaparib in GEP-NETs Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) NET RETREAT: Retreatment with 177Lu-DOTATATE vs Everolimus in Metastatic Midgut NET NETTER-P: Lutathera in Adolescent Patients (12-17) with GEP-NETs and PPGLs Olaparib + Usual Chemotherapy (Temozolomide) in PPGL Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029) Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs SWOG S2104: Adjuvant CAPTEM for High Risk pNET SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC By type of disease or treatment Browse by trial Clinical Trials Guide Browse by Type of Disease or Treatment: Pancreatic NET (PNET) Click Here Lung/Bronchial NETs Click Here G3 Neuroendocrine Neoplasms (NEN) or High Grade Click Here Immunotherapy Click Here NIH/NCI Natural History Study for Neuroendocrine Neoplasms Click Here Additional Resources Click Here Gastrointestinal (GI) NETs Click Here Pheochromocytoma/ Paraganglioma Click Here Peptide Receptor Radionuclide Therapy (PRRT) Click Here Somatostatin Analogue (SSA) Click Here Other Click Here UNDERSTANDING CLINICAL TRIALS Finding and learning more about relevant neuroendocrine cancer clinical trials may feel overwhelming. While comprehensive databases are available to search for trials, it may be difficult to understand whether a trial is right for you. Our goal is to offer a resource with key, open clinical trials for those with neuroendocrine cancer (aka, neuroendocrine neoplasm or NEN, including neuroendocrine tumor or NET and neuroendocrine carcinoma or NEC). We hope this information will help you better understand clinical trials and empower you to discuss them with your medical team. You may browse the Clinical Trials Guide in the following ways: Browse by selecting a type of disease or treatment. For example, if you are interested in open trials for pancreatic neuroendocrine tumor (PNET), click on the “PNET” image below. If you are interested in exploring peptide receptor radionuclide therapy (PRRT) trials, click on the “PRRT” image below. Browse by the trial using the table of contents. Click on individual trials to learn more information. Use the Ancora.ai clinical trial finder by entering your location and specifics about your tumor to find appropriate clinical trials. Then, browse this clinical trial guide to learn more about the suggested trials. When exploring the Clinical Trials Guide, you will find a description of each trial and contact information. Many also include a video of a NET expert describing the trial. The videos explain the study and who is eligible to participate. You can consider clinical trials at any time during your NET journey. Options range from first-line treatments for those newly diagnosed to novel treatments for those who have already had multiple treatments. For more information on how your involvement may benefit you and the NET community, read Why Participate in Clinical Trials . Download "Glossary of Common Terms in Clinical Trials" >>> Download "Clinical Trials: How to Prepare" >>> Ancora Ancora.ai Ancora.ai is a neuroendocrine tumor clinical trial finder for patients and physicians developed by Ancora.ai and NorCalCarciNET. Ancora allows you to do a personalized search, filter and export results, and if interested, Ancora's patient team can help connect you to a trial site to begin the evaluation process. It's free and easy to use. Click here to access Ancora.ai >> DISCLAIMER: This information is for educational purposes only. The Neuroendocrine Cancer Foundation encourages you to discuss your individual care and treatment options with your medical team. The Neuroendocrine Cancer Foundation does not endorse any particular trial or treatment. This is not a complete list of available NET trials nor is it intended to be. For comprehensive information about available clinical trials, go to ClinicalTrials.Gov.

<< Back NIH/NCI Natural History Study for Neuroendocrine Neoplasms Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

<< Back Somatostatin Analogue (SSA) Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma

<< Back Immunotherapy Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas CHM-2101 CAR-T cell for GI Cancers DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

<< Back Peptide Receptor Radionuclide Therapy (PRRT) PRRT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC COMPOSE (GEP-NETs) Alpha PRRT with Pb-212 VMT ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET Alpha PRRT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Combo Trial with Lu177 + Additional Medication Lu177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine in GEP-NETs Lu177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs PRRT for Specific Populations Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients PRRT Comparison Trial of Lu177 versus Another Medication COMPOSE (GEP-NETs) ComPareNET Lu-177 vs CAPTEM in PNETs

<< Back G3 Neuroendocrine Neoplasms (NEN) or High Grade Grade 3 NET Alpha PRRT with Pb-212 VMT CHM-2101 CAR-T cell for GI Cancers COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Olaparib in GEP-NETs SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029) SWOG S2104: Adjuvant CAPTEM for High Risk pNET Neuroendocrine Carcinoma (NEC) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Sunitinib in PNETs SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

<< Back Pheochromocytoma/ Paraganglioma Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Belzutifan/MK-6482 in PNET + PPGL + VHL IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Olaparib + Usual Chemotherapy (Temozolomide) in PPGL NETTER-P: Lutathera in Adolescent Patients LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma

<< Back Lung/Bronchial NETs PRRT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE vs Everolimus in Lung NETs Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)